Skip to main
PSTV
PSTV logo

PSTV Stock Forecast & Price Target

PSTV Analyst Ratings

Based on 4 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Plus Therapeutics Inc is positioned favorably due to its substantial drug development progress targeting recurrent glioblastoma and leptomeningeal metastases, with significant milestones anticipated in 2025 and 2026. The company’s financial outlook is bolstered by an $18 million grant awarded by the Cancer Prevention and Research Institute of Texas, which will support its research efforts in treating leptomeningeal metastases. Additionally, a positive net present value (NPV) analysis reinforces the stock’s potential, indicating considerable upside based on current performance metrics.

Bears say

Plus Therapeutics Inc faces significant risks that contribute to a negative outlook, including the potential failure of its product candidates to demonstrate safety and efficacy in clinical trials, which could hinder regulatory approvals and commercial viability. Additionally, the company's pro forma earnings per share (EPS) of $0.02, while positive, is notably below prior estimates of $(0.13) and consensus expectations of $(0.12), indicating potential financial instability. Moreover, external factors such as competition and changing macroeconomic conditions further exacerbate the uncertainties surrounding the company's ability to sustain or grow its market position.

PSTV has been analyzed by 4 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Plus Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Plus Therapeutics Inc (PSTV) Forecast

Analysts have given PSTV a Strong Buy based on their latest research and market trends.

According to 4 analysts, PSTV has a Strong Buy consensus rating as of Oct 15, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $8, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $8, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Plus Therapeutics Inc (PSTV)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.